We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Serum and Plasma Choline Quantified by Clinical NMR- Analyzer

By LabMedica International staff writers
Posted on 14 Dec 2021
Print article
Image: The Vantera Clinical Analyzer can identify and quantify concentrations of choline using NMR spectroscopy (Photo courtesy of American Association for Clinical Chemistry)
Image: The Vantera Clinical Analyzer can identify and quantify concentrations of choline using NMR spectroscopy (Photo courtesy of American Association for Clinical Chemistry)
Gut microbiome-related metabolites, like trimethylamine-N-oxide (TMAO), betaine and choline are increasingly recognized as contributors to, as well as markers of, cardiometabolic and other chronic diseases. Gut microbiome mediated metabolism of phosphatidylcholine leads to the production of choline, which is then metabolized to either trimethylamine (TMA) or betaine.

Choline is important because it is a component of membrane phospholipids including phosphatidylcholine, the most abundant phospholipid in humans. Choline is also needed for methyl group metabolism, cholinergic neurotransmission as well as lipid and cholesterol transport and metabolism. A high-throughput nuclear magnetic resonance (NMR)–based assay to measure choline has been developed.

Scientists from the Laboratory Corporation of America Holdings (Morrisville, NC, USA) pooled de-identified residual clinical specimens that were pooled to enable the analytical validation studies. In addition, blood draws were performed when appropriate de-identified specimens were not available. Serum or plasma specimens were diluted on board the Vantera Clinical Analyzer (LipoScience Inc, Raleigh, NC, USA) with citrate/phosphate buffer to lower the pH to 5.3. Choline was quantified from the processed spectra using a proprietary multi-step deconvolution algorithm that resolves the choline region into its spectral components. A method comparison study was performed to compare choline concentrations determined by both NMR and liquid chromatography tandem mass spectrometry (LC-MS/MS), 1290 UHPLC system coupled to a 6495B QQQ mass spectrometer (Agilent Technologies, Santa Clara, CA, USA).

The investigators reported that Deming regression analysis comparing choline concentrations by NMR and mass spectrometry (n=28) exhibited a correlation coefficient of 0.998. The limit of quantification were determined to be 7.1 µmol/L in serum and 5.9 µmol/L in plasma. The coefficients of variation (%CV) for intra- and inter-assay precision ranged from 6.2–14.8% (serum) and 5.4–11.3% (plasma). Choline concentrations were lower in EDTA plasma by as much as 38% compared to serum, however, choline was less stable in serum compared to plasma. In a population of apparently healthy adults, the reference interval was <7.1–20.0 µmol/L (serum) and <5.9–13.1 µmol/L (plasma). Linearity was demonstrated well beyond these intervals. No interference was observed for a number of substances tested.

The authors concluded that the newly developed NMR-based assay exhibited good performance characteristics enabling high-throughput quantification of circulating choline for clinical use. While lower choline concentrations were observed in plasma compared to serum, choline was more stable in plasma. The study was published on December 4, 2021 in the journal Clinica Chimica Acta.

Related Links:
Laboratory Corporation of America Holdings
LipoScience Inc
Agilent Technologies

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
RIELE Photometer 505
Microbial Infections In-Vitro Diagnostic Solution
Weezion dx
Automatic Specific Protein Analyzer
PA 900

Print article


Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more


view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.